Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study
Status
Conditions
Treatments
Details and patient eligibility
About
This is a single-site, sham-controlled, randomized trial in a total of 60 subjects between ages 18 and 40 years with schizophrenia. This study will investigate the effects of 4-week rTMS treatment on brain and cognitive functions in patients. Subjects will be randomized to one of the following arms:
Arm 1: Standard of Care (SOC) and active rTMS Arm 2: Standard of Care (SOC) and sham rTMS
Each participant will receive rTMS five days per week, for four consecutive weeks. Functional magnetic resonance imaging (fMRI) scans, clinical assessments, and cognitive tests will be performed at baseline, end of the 2nd week, and end of the 4th week.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Male or female subjects 18 to 40 years of age
- DSM-V diagnosis of schizophrenia spectrum disorders
- Competent to provide informed consent
Exclusion criteria
- Lifetime DSM-V diagnosis of an Axis-I disorder other than schizophrenia spectrum disorders
- Lifetime diagnosis of ataxia or other cerebellar disorders
- Lifetime diagnosis of mental retardation, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, or other neurodegenerative disorders
- Any active general medical condition or CNS disease which can affect cognition or response to treatment
- Substance dependence or abuse in the past six months
- Seizure history
- TMS within three months or ECT within six months
- Pregnancy as indicated by self-report
- MRI contraindications
Trial design
Primary purpose
Allocation
Interventional model
Masking
60 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal